NewAmsterdam Pharma (NAMS) officer Robert Gunning files initial Form 3 ownership

Rhea-AI Filing Summary

NewAmsterdam Pharma Co N.V. reported that Robert William Gunning, who serves as Vice President, Controller, filed an initial statement of beneficial ownership on Form 3. The filing lists no reportable equity transactions or holdings at this time.

FAQ

What does the Form 3 filed by NewAmsterdam Pharma (NAMS) report for Robert William Gunning?

The Form 3 identifies Robert William Gunning as Vice President, Controller of NewAmsterdam Pharma Co N.V. It shows no reportable equity transactions or holdings for him as of this initial filing.

Does the NewAmsterdam Pharma (NAMS) Form 3 show any stock purchases or sales by Robert William Gunning?

No. The Form 3 transaction summary shows zero buy, sell, acquire, dispose, or other transactions, and there are no derivative transactions reported for Robert William Gunning.

Are any stock or option holdings reported for Robert William Gunning in the NAMS Form 3?

No holdings are reported. The filing indicates no non-derivative holdings and a derivative summary with no remaining derivative positions disclosed for Robert William Gunning in this initial ownership statement.

Is there any indication of a Rule 10b5-1 trading plan in the NAMS Form 3 for Robert William Gunning?

No. The document-level Rule 10b5-1 field is null, and no footnotes describe any 10b5-1 trading plan for Robert William Gunning in this filing.

What insider role does Robert William Gunning hold at NewAmsterdam Pharma (NAMS)?

Robert William Gunning is reported as an officer of NewAmsterdam Pharma Co N.V., serving in the role of Vice President, Controller, and is not listed as a director or 10% owner in this Form 3.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 08/14/2026 - 04:15 PM Accepted by SEC EDGAR 08/14/2026 - 04:07 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Gunning Robert William

(Last) (First) (Middle)

C/O NEWAMSTERDAM PHARMA COMPANY N.V.

GOOIMEER 2-35

(Street)

NAARDEN 1411 DC

(City) (State) (Zip)

NETHERLANDS

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/10/2026

3. Issuer Name and Ticker or Trading Symbol
NewAmsterdam Pharma Co N.V. [ NAMS ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Vice President, Controller

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Michael Marino, Attorney-in-Fact	08/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)